(Japanese)
(Japanese)
(Japanese)
OUR PRODUCT
Progress of Drug R&D Highly Depends On the Supply of the Blood For Research
ABOUT OUR PRODUCT
Mpv
immature red blood-like cells for
Malaria (P.vivax) research
erythroid
progenitor cell
modified erythrocytic progenitor cell
for Malaria
Mpv cell kit
red blood-like cell
suitable for
Malaria research
■ co-developed with Kyoto and Nagasaki Universities
M02
Mylc
special myeloid lineage cells for
Dengue and other infectious diseases
leukocyte
progenitor cell
modified myeloid
lineage cell
for Virus research
M02 cell kit
Mylc
myeloid lineage cell
suitable for
Dengue or Virus research
■ co-developed with Universities
■ start supplying products from 12th Dec, 2019
OUR PRODUCT VALUE
OUR TECHNOLOGY
Gene-Editing Technology
Our gene-editing technology can realize gene modifications of progenitor cells. (various gene-editing are possible upon request)
Our products have high level of uniformity, suitable for drug R&D
Differentiation- Induction Technology
Consistent- Production Technology
Providing sufficient amount of blood cells for evaluation inexpensively, after 3-year improvement of production efficiency.
IN THE PIPELINE
■ Final products will start to be shipped in the following year of releasing its pilot version.
■ We are planning to develop drugs and vaccines for infective diseases.
HIGH UNIFORMITY
Controlling differentiate stages of cells,
we achieved to produce
high uniformity of cells suitable
for precise drug developments.
RELIABLE SUPPLY
Produced with cutting edge technologies of regenerative medicine, high quality experimental cells are available at
anytime with sufficient amount.
LOW COST
Comparing to conventional human blood/ blood cells for experiments,
our products are far more affordable
in superior quality.
Our products are bottled
and securely packed, and delivered under the best possible condition.
ABOUT
DELIVERY
Prompt Delivery
Next-day delivery from Kyoto, Japan to Bangkok, Thailand is possible*. In our trials, most of the cells delivered survived for several more days.
* A package of MPV cells departed our Kyoto lab at 13:20, arriving at Bangkok Airport at 13:15 the following day. The actual timing depends on traffic and flight conditions.
Why
Needed?
Progress of Drug R&D Highly Depends On the Supply of the Blood For Research
Present issues regarding vivax malaria:
-
8.5 million people affected every year
-
Suffering from drug resistance due to the use of generic drugs
Limited access to vivax malaria parasites;
-
Only grow in immature cells
-
Seasonal outbreak window of only two months
Tropical countries face the challenge of
combating many infectious diseases:
-
Ebola, Zika, Dengue, to name a few
-
W/W economic support from WHO/UN/private funds
-
Population reaching the threshold where they can afford medicine